Drug intelligence / Profile preview

lamotrigine + levetiracetam + valproic acid

Development stage: Unknown
Lead developer: GSK
Modality: Small Molecules
Administration: Oral, Intravenous

Overview

A combination of three distinct antiepileptic drugs (AEDs) that work through different mechanisms to control seizures. Lamotrigine is a phenyltriazine that stabilizes neuronal membranes, levetiracetam modulates synaptic neurotransmitter release, and valproic acid enhances GABA inhibitory effects. This combination may be used when monotherapy is insufficient for seizure control, particularly in difficult-to-treat epilepsy cases.

Targets

ABAT (4-aminobutyrate aminotransferase)SSADH (Succinate-semialdehyde dehydrogenase)NaV (Voltage-gated sodium channels)SV2A (Synaptic vesicle glycoprotein 2A)

Beyond the preview

Go deeper on lamotrigine + levetiracetam + valproic acid.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on lamotrigine + levetiracetam + valproic acid.

Explore the full profile